RxDoctor Payments Data

Morgan Cook Osborne

Psychiatric/Mental Health · Coeur D Alene, IDNPI 1922715705

Payments from drug & device makers

$1,227in general payments, 2019–2025

Across 55 payments — averaging $22.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$396
  • AbbVie$123
  • Johnson & Johnson$108
  • Lundbeck LLC$94
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$91
  • Otsuka America Pharmaceutical, Inc.$87
  • plus $327 from 9 others

What the payments were for

  • Food & beverage$1,04385%
  • Education$18415%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,227 in reported general payments places this provider in the 65th percentile of 221 psychiatric/mental health providers in Idaho.

See all psychiatric/mental health providers in Idaho

Medicare billing

Part B allowed, 2024
$262
Medicare patients
12
Services billed
59

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl30$39,604
CaplytaLumateperone Tosylate11$34,657
TrintellixVortioxetine Hydrobromide20$13,199
QelbreeViloxazine Hcl13$7,280
Aripiprazole42$6,992
Lurasidone Hcl23$4,944
Olanzapine41$3,163
Dexmethylphenidate Hcl ErDexmethylphenidate Hcl11$2,944
Methylphenidate ErMethylphenidate Hcl14$1,850
Quetiapine Fumarate ErQuetiapine Fumarate12$1,711
Buspirone Hcl62$833
Duloxetine Hcl29$539
Guanfacine Hcl ErGuanfacine Hcl11$517
Hydroxyzine Hcl11$418
Gabapentin44$383

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$123$39,60430 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$91$34,65711 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$19$13,19920 claims
Supernus Pharmaceuticals, Inc.Qelbree$40$7,28013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 221 psychiatric/mental health providers in Idaho.

Other psychiatric/mental health in Coeur D Alene

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →